Cetalkonium Chloride + Choline Salicylate interactions
Checked as Choline salicylate in this data source.
Full monograph for Cetalkonium Chloride + Choline SalicylateCheck it against another medicine
Medicines
272 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acetazolamide | Major | Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox… | 3 sources — open the full entry |
| Dorzolamide + Timolol | Major | Antagonism · Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate…2 documented mechanisms | 22 sources — open the full entry |
| Ketorolac Tromethamine | Major | Synergy | The use of ketorolac in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious adverse effects such as renal… | 1 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity… | 3 sources — open the full entry |
| Methotrexate | Major | Excretion | Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of… | 17 sources — open the full entry |
| Monobasic Sodium Phosphate + Dibasic Sodium Phosphate | Major | Others | The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing… | 3 sources — open the full entry |
| Ramucirumab | Major | Synergy | Theoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal… | 1 sources — open the full entry |
| Activated Charcoal | Moderate | Absorption | Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects… | 25 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Alendronic acid | Moderate | Synergy | Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates… | 12 sources — open the full entry |
| Alendronic Acid + Vitamin D3 | Moderate | Synergy | Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates… | 12 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| Alteplase | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 8 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 8 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Amikacin | Moderate | Synergy | The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in… | 6 sources — open the full entry |
| Amlodipine Besilate | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to… | 41 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 47 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to… | 41 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 57 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 47 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 47 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 47 sources — open the full entry |
| Apixaban | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| Aspirin | Moderate | Synergy | Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding… | 2 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy | Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding… | 2 sources — open the full entry |
| Azilsartan Medoxomil | Moderate | Antagonism | Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is…2 documented mechanisms | 10 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Antagonism | Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is…2 documented mechanisms | 10 sources — open the full entry |
| Baricitinib | Moderate | Synergy | Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of… | 15 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Synergy | Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding… | 2 sources — open the full entry |
| Betamethasone | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Calcipotriol | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Excretion · Synergy | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may…2 documented mechanisms | 11 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Dipropionate | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Excretion · Synergy | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may…2 documented mechanisms | 7 sources — open the full entry |
| Betamethasone Sodium Phosphate | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Valerate | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betrixaban | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| Biphasic Insulin Aspart | Moderate | Synergy | The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines… | 86 sources — open the full entry |
| Bismuth Subsalicylate | Moderate | Synergy | Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding… | 2 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 47 sources — open the full entry |
| Bivalirudin | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Excretion | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
Therapeutic duplication
Drug classes that overlap with Cetalkonium Chloride + Choline Salicylate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Consensi
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Synalgos-dc
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Esomeprazole/naproxen
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Phosphasal
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Acetaminophen/caffeine/magnesium salicylate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Orphengesic forte
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/citric acid/sodium bicarbonate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Acetaminophen/magnesium salicylate/pamabrom
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Soma compound with codeine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Stanback
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Methenamine/sodium salicylate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/butalbital/caffeine/codeine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/methocarbamol
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Micrainin
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/carisoprodol
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/chlorpheniramine/dextromethorphan/phenylpropanolamine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Percodan
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/omeprazole
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Doans pm
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/dipyridamole
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/chlorpheniramine/phenylephrine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Migraine relief
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Prosed ds
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Laniroif
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/hydrocodone